Detalhe da pesquisa
1.
Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk
J. Am. Coll. Cardiol;
78(20): 1968-1986, Nov. 2021. graf, tab
Artigo
em Inglês
| CONASS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1353261
2.
Safety and Clinical performance of the drug-eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries at 36- month follow-up: BIOSOLVE-II and BIOSOLVE-III
J. Am. Coll. Cardiol;
74(13 supl): 187-187, Oct., 2019.
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1024965
3.
Serial multimodality imaging and 2-Year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions
JACC cardiovasc. interv;
9(6): 565-574, 2016.
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1064070
4.
A randomised comparison of novolimus-eluting and zotarolimuselutingcoronary stents: 9-month follow-up results of the EXCELLA II study
EuroIntervention;
6(2): 1-15, 2014. ilus
Artigo
em Inglês
| SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1062721